About Sierra Oncology (NASDAQ:SRRA)
Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.
Industry, Sector and Symbol
Trailing P/E Ratio-2.72941176470588
Forward P/E Ratio-2.67
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.81 per share
Price / Book1.28
Return on Equity-38.91%
Return on Assets-36.82%
Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions
What is Sierra Oncology's stock symbol?
Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."
How were Sierra Oncology's earnings last quarter?
Sierra Oncology Inc (NASDAQ:SRRA) announced its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.02. During the same period in the previous year, the firm posted ($0.30) earnings per share. View Sierra Oncology's Earnings History.
What are Wall Street analysts saying about Sierra Oncology stock?
Here are some recent quotes from research analysts about Sierra Oncology stock:
- 1. According to Zacks Investment Research, "Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central regulator of the DNA Damage Response network. SRA141 is an orally available small molecule inhibitor of cell division cycle 7kinase. Sierra Oncology, Inc., formerly known as ProNAi Therapeutics, Inc., is headquatered in Vancouver, Canada. " (3/2/2018)
- 2. Jefferies Group LLC analysts commented, "under-the-radar" clinical program shows innovation and value.As such, Jefferies upgraded shares of the company from Hold to Buy and lifted its price target from $1.50 to $5.At the time of writing, shares of Sierra Oncology were jumping 9.76 percent to $1.80.Analyst Maury Raycroft noted that Sierra Oncology is rapidly advancing SRA737 through dose-escalation in two clinical studies. SRA737 is a potent, highly selective, orally available, small molecule inhibitor of Checkpoint kinase 1, which is being investigated in two phase 1 clinical trials in patients with advanced cancer.The analyst believes the market opportunity will continue to evolve and grow along with increased genetic testing and understanding, with potential for ‘737 success in several tumor-agnostic indications.The analyst noted that the company is running two trials, one assessing ‘737 as a monotherapy and another with ‘737+ low-dose gem. In mono settings, the analyst noted that ‘737 can follow a similar path as PARPs and may be used in points with DNA repair mutations. See also: Attention Biotech Investors, Here's Your PDUFA Primer For October Meanwhile, in combo study, the analyst said the company is using a biology-driven design, where a low dose is used to induce replication stress, increasing cancer cell reliance on Chk1. Additionally, the analyst said pharma enthusiasm and data validate Chk1 inhibition as a clinically-relevant mechanism of action. Also, SRA737 safety update at ASCO'17 de-risks further, the analyst added.Among the upcoming catalysts are:‘737 data due in Feb 2018 and the second-half of 2018.Updates throughout the next 12-18 months for competitor Chk1s such as Eli Lilly and Co LLY)'s prexasertib and Array Biopharma Inc (NASDAQ: ARRY)'s GDC-0575.Pre-clinical Chk1 abstracts, supporting the company's strategy, such as SRA737+low-dose gem abstract and a prexasertib one on Chk1 PD-L1 regulation."Importantly, we believe SRRA's clinical strategy is differentiated and innovative — a smarter strategy — selecting for pts w/ specific genetic driver mutations that may make them most likely to respond to '737," Jefferies added."We would buy ahead of 1Q18 data." (10/23/2017)
Who are some of Sierra Oncology's key competitors?
Some companies that are related to Sierra Oncology include AVEO Pharmaceuticals (AVEO), NicOx (NICXF), Solid Biosciences (SLDB), Nantkwest (NK), Viralytics (VRACY), MannKind (MNKD), Savara (SVRA), Enzo Biochem (ENZ), Catalyst Biosciences (CBIO), Zymeworks (ZYME), BioSpecifics Technologies (BSTC), Osiris Therapeutics (OSIR), DURECT (DRRX), Arbutus Biopharma (ABUS), Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share (AVDL), Chromadex (CDXC), Catalyst Pharmaceuticals (CPRX) and Viking Therapeutics (VKTX).
Who are Sierra Oncology's key executives?
Sierra Oncology's management team includes the folowing people:
- Donald R. Parfet, Independent Chairman of the Board (Age 65)
- Nicholas R. Glover Ph.D., President, Chief Executive Officer, Director (Age 48)
- Sukhi Jagpal, Chief Financial Officer (Age 42)
- Barbara Klencke M.D., Chief Development Officer (Age 58)
- Mark Kowalski M.D. Ph.D., Chief Medical Officer (Age 62)
- Angie J. You Ph.D., Chief Business & Strategy Officer and Head of Commercial (Age 43)
- Andrew R. Allen M.D. Ph.D., Director (Age 50)
- Jeffrey H. Cooper, Independent Director (Age 61)
- Daniel Estes Ph.D., Independent Director (Age 36)
- Tran Nguyen, Independent Director (Age 43)
Has Sierra Oncology been receiving favorable news coverage?
Headlines about SRRA stock have been trending somewhat positive on Sunday, according to Accern. Accern identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Sierra Oncology earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Sierra Oncology's major shareholders?
Sierra Oncology's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.56%), Millennium Management LLC (2.34%), 683 Capital Management LLC (1.76%), Iguana Healthcare Management LLC (1.53%), Renaissance Technologies LLC (1.41%) and AWH Capital L.P. (1.31%). Company insiders that own Sierra Oncology stock include Angie You, James N Topper and Wendy Chapman. View Institutional Ownership Trends for Sierra Oncology.
Which major investors are buying Sierra Oncology stock?
SRRA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, 683 Capital Management LLC, AWH Capital L.P., Candriam Luxembourg S.C.A., Sphera Funds Management LTD., Renaissance Technologies LLC, Millennium Management LLC and Iguana Healthcare Management LLC. Company insiders that have bought Sierra Oncology stock in the last two years include Angie You and James N Topper. View Insider Buying and Selling for Sierra Oncology.
How do I buy shares of Sierra Oncology?
Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sierra Oncology's stock price today?
One share of SRRA stock can currently be purchased for approximately $2.32.
How big of a company is Sierra Oncology?
Sierra Oncology has a market capitalization of $165.64 million. The biotechnology company earns $-42,010,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Sierra Oncology employs 57 workers across the globe.
How can I contact Sierra Oncology?
Sierra Oncology's mailing address is 2150 -885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at 604-558-6536 or via email at [email protected]
MarketBeat Community Rating for Sierra Oncology (SRRA)MarketBeat's community ratings are surveys of what our community members think about Sierra Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sierra Oncology (NASDAQ:SRRA) Earnings History and Estimates Chart
Sierra Oncology (NASDAQ SRRA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Sierra Oncology (NASDAQ:SRRA) Earnings Estimates
2018 EPS Consensus Estimate: ($0.85)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Sierra Oncology (NASDAQ:SRRA)
No dividend announcements for this company have been tracked by MarketBeat.com
Sierra Oncology (NASDAQ SRRA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.72%
Institutional Ownership Percentage: 58.97%
Sierra Oncology (NASDAQ SRRA) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/8/2017||Angie You||Insider||Buy||30,000||$1.43||$42,900.00||133,252|| |
|2/14/2017||James N Topper||Director||Buy||5,925,926||$1.35||$8,000,000.10|| |
|3/22/2016||Wendy Chapman||SVP||Sell||3,000||$7.01||$21,030.00||3,000|| |
|2/22/2016||Wendy Chapman||SVP||Sell||3,000||$7.06||$21,180.00||3,000|| |
|1/22/2016||Wendi Rodigueza||insider||Sell||3,000||$9.86||$29,580.00||156,276|| |
|1/22/2016||Wendy Chapman||SVP||Sell||5,000||$9.39||$46,950.00|| |
|1/15/2016||Nicholas Glover||CEO||Sell||5,000||$10.04||$50,200.00|| |
|1/12/2016||Chandra D. Lovejoy||SVP||Sell||20,973||$11.29||$236,785.17|| |
|7/21/2015||Orbimed Advisors Llc||Director||Buy||175,000||$17.00||$2,975,000.00|| |
|7/21/2015||Vivo Ventures Vii, Llc||Insider||Buy||220,000||$17.00||$3,740,000.00|| |
Sierra Oncology (NASDAQ SRRA) News Headlines
|Due Diligence Ramp-Up: Sierra Oncology's DNA Damage Gamble - Seeking Alpha|
seekingalpha.com - March 10 at 5:43 PM
|PTC Therapeutics (PTCT) & Sierra Oncology (SRRA) Critical Review|
www.americanbankingnews.com - March 9 at 9:36 PM
|-$0.21 EPS Expected for Sierra Oncology Inc (SRRA) This Quarter|
www.americanbankingnews.com - March 6 at 7:17 PM
|SunTrust Banks Comments on Sierra Oncology Inc's FY2022 Earnings (SRRA)|
www.americanbankingnews.com - March 5 at 9:26 AM
|Sierra Oncology Inc to Post FY2019 Earnings of ($0.78) Per Share, Wedbush Forecasts (SRRA)|
www.americanbankingnews.com - March 5 at 8:14 AM
|AWH Capital L.P. Acquires Shares of 685,000 Sierra Oncology Inc (SRRA)|
www.americanbankingnews.com - March 5 at 4:52 AM
|Sierra Oncology (SRRA) Downgraded by Zacks Investment Research to "Sell"|
www.americanbankingnews.com - March 2 at 9:56 PM
|Analysts Set Expectations for Sierra Oncology Inc's FY2022 Earnings (SRRA)|
www.americanbankingnews.com - March 2 at 5:30 PM
|Jefferies Group Equities Analysts Decrease Earnings Estimates for Sierra Oncology Inc (SRRA)|
www.americanbankingnews.com - March 2 at 1:00 PM
|Sierra Oncology (SRRA) Plans Offering of Common Stock|
www.streetinsider.com - March 2 at 8:59 AM
|Sierra Oncology Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - March 1 at 5:11 PM
|Jefferies Group Weighs in on Sierra Oncology Inc's Q1 2018 Earnings (SRRA)|
www.americanbankingnews.com - March 1 at 7:20 AM
|Sierra Oncology (SRRA) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS|
www.americanbankingnews.com - February 28 at 10:32 AM
|Sierra Oncology (SRRA) and Janssen Sign Supply Agreement for Prostate Cancer Study|
www.streetinsider.com - February 28 at 9:00 AM
|Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study|
finance.yahoo.com - February 27 at 9:05 AM
|Sierra Oncology Significantly Expands Clinical Development Program|
finance.yahoo.com - February 27 at 9:05 AM
|Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting|
finance.yahoo.com - February 21 at 9:04 AM
| Brokerages Anticipate Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per Share|
www.americanbankingnews.com - February 18 at 3:14 AM
|Sierra Oncology (SRRA) Presents At BIO CEO & Investor Conference - Slideshow|
seekingalpha.com - February 13 at 4:12 PM
|Sierra Oncology to host Program Update in New York on February 27th|
finance.yahoo.com - February 6 at 9:23 AM
|Brokerages Expect Sierra Oncology Inc (SRRA) to Post ($0.20) Earnings Per Share|
www.americanbankingnews.com - January 17 at 1:18 PM
|Zacks: Brokerages Expect Sierra Oncology Inc (SRRA) Will Post Earnings of -$0.20 Per Share|
www.americanbankingnews.com - January 15 at 5:36 AM
|4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE)|
finance.yahoo.com - January 10 at 4:18 PM
|Analyzing Sierra Oncology (SRRA) & Its Rivals|
www.americanbankingnews.com - January 8 at 11:06 PM
|Head-To-Head Review: Sierra Oncology (SRRA) and Its Rivals|
www.americanbankingnews.com - January 5 at 7:18 AM
|Sierra Oncology to Present at the Biotech Showcase in San Francisco|
finance.yahoo.com - January 3 at 9:13 AM
|Sierra Oncology (SRRA) versus Its Peers Financial Survey|
www.americanbankingnews.com - January 2 at 1:20 PM
|Comparing Sierra Oncology (SRRA) and Its Peers|
www.americanbankingnews.com - December 30 at 7:42 AM
|Zacks: Brokerages Anticipate Sierra Oncology Inc (SRRA) to Announce -$0.20 Earnings Per Share|
www.americanbankingnews.com - December 29 at 9:28 AM
|Sierra Oncology (SRRA) & Its Rivals Critical Comparison|
www.americanbankingnews.com - December 29 at 3:28 AM
|Analysts Anticipate Sierra Oncology Inc (SRRA) to Post ($0.20) EPS|
www.americanbankingnews.com - December 28 at 5:04 PM
|Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher - Nasdaq|
www.nasdaq.com - December 28 at 8:01 AM
|Sierra Oncology (SRRA) in Focus: Stock Moves 10.5% Higher|
finance.yahoo.com - December 27 at 2:27 PM
| Sierra Oncology Inc (SRRA) Receives Average Recommendation of "Strong Buy" from Brokerages|
www.americanbankingnews.com - December 16 at 3:24 PM
|-$0.20 Earnings Per Share Expected for Sierra Oncology Inc (SRRA) This Quarter|
www.americanbankingnews.com - December 12 at 5:06 AM
|Penny Stocks to Watch for December 2017|
finance.yahoo.com - November 30 at 11:20 AM
| Brokerages Set $4.33 Target Price for ProNAi Therapeutics, Inc. (SRRA)|
www.americanbankingnews.com - November 28 at 9:10 PM
|ProNAi Therapeutics, Inc. (SRRA) Upgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - November 25 at 11:28 AM
|ProNAi Therapeutics, Inc. to Post FY2017 Earnings of ($0.84) Per Share, SunTrust Banks Forecasts (SRRA)|
www.americanbankingnews.com - November 13 at 2:14 AM
|Analysts Issue Forecasts for ProNAi Therapeutics, Inc.'s FY2017 Earnings (SRRA)|
www.americanbankingnews.com - November 13 at 2:14 AM
|Financial Review: ProNAi Therapeutics (SRRA) & DURECT Corporation (DRRX)|
www.americanbankingnews.com - November 10 at 9:25 AM
|ProNAi Therapeutics, Inc. (SRRA) Issues Earnings Results, Beats Expectations By $0.03 EPS|
www.americanbankingnews.com - November 9 at 2:51 PM
|Sierra Oncology Reports Third Quarter Results|
finance.yahoo.com - November 9 at 2:01 PM
|Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference|
finance.yahoo.com - November 7 at 11:01 AM
|Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy|
finance.yahoo.com - October 30 at 7:21 AM
|Zacks Investment Research Lowers ProNAi Therapeutics, Inc. (SRRA) to Sell|
www.americanbankingnews.com - October 26 at 7:10 AM
|Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors|
finance.yahoo.com - October 25 at 11:11 AM
|ProNAi Therapeutics, Inc. (SRRA) Forecasted to Earn Q3 2017 Earnings of ($0.20) Per Share|
www.americanbankingnews.com - October 25 at 7:34 AM
|FY2021 Earnings Estimate for ProNAi Therapeutics, Inc. (SRRA) Issued By Jefferies Group|
www.americanbankingnews.com - October 24 at 3:52 PM
| Brokerages Expect ProNAi Therapeutics, Inc. (SRRA) Will Announce Earnings of -$0.22 Per Share|
www.americanbankingnews.com - October 16 at 6:26 PM
Sierra Oncology (NASDAQ:SRRA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sierra Oncology (NASDAQ:SRRA) Income Statement, Balance Sheet and Cash Flow Statement
Sierra Oncology (NASDAQ SRRA) Stock Chart for Sunday, March, 18, 2018